We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Faster Way of Detecting Bacteria Developed

By LabMedica International staff writers
Posted on 16 Feb 2017
A faster way to detect the pathogenic bacteria that may cause patients to become sick has now been developed, giving physicians a better chance at saving lives by proscribing the most suitable antibiotic.

Today, patients generally have to wait days to get final test result, but the new method of testing of urine samples, for example, produces positive results in two hours from start to finish versus the days it can take for equivalent hospital laboratory tests.

Scientists at Michigan State University developed a point-of-care diagnostic test known as In-Dx. More...
The detection process is relatively simple for both the patient and physician. A sample is collected and concentrated into a smaller amount. After applying heat, which breaks down the sample cells, it is then placed into the In-Dx testing panel and after 20 minutes of incubation time, the positive sample changes color, revealing the invading organism. The team is more than one year into a clinical trial that aims to validate the point-of-care diagnostic test, and the preliminary results already look promising.

The molecular diagnostic system can identify dangerous bacteria such as Escherichia coli, Staphylococcus infections, and even some superbugs. The test can produce results within two hours using blood, urine, saliva, wound, stool or cerebral spine fluid samples from infected patients. The team have concentrated on sepsis, a serious, life-threatening infection occurring more commonly in hospitalized patients, is one of the medical problems. If not treated properly, septic patients may have only hours to live. Currently, millions of people die each year worldwide partly because a definitive diagnosis of the sepsis-causing bacteria often takes too long.

Brett Etchebarne, MD, PhD, an assistant professor of emergency medicine, who helped develop the test said, “In-Dx has high sensitivity and specificity for detection of the most common infectious organisms which will help physicians quickly rule in or rule out specific bacteria. Knowing what your target is early in the fight against sepsis will be an invaluable advantage in helping maximize patient care strategies and outcomes.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Urine Analyzer
respons® UDS100
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.